Fri, Aug 1, 2014, 4:42 AM EDT - U.S. Markets open in 4 hrs 48 mins


% | $
Click the to save as a favorite.

Incyte Corporation Message Board

  • janmichealvincentsfriend janmichealvincentsfriend Nov 7, 2013 9:34 AM Flag

    GERN's Results Doom INCY? It Is Possible... Now What Will You INCY Holders Do?

    " Overall response rate was 44%. This included five (28%) patients who met the BM and peripheral blood morphologic criteria for CR (n=4) or PR (n=1) and 3 patients with clinical improvement, pending validation of response duration and resolution of drug-induced grade-1 thrombocytopenia. The four (22%) CR patients experienced reversal of BM fibrosis and recovery of normal megakaryocyte morphology. Two CR patients were transfusion-dependent at baseline and became transfusion-independent. Complete molecular responses were documented in 2 CR patients: one had U2AF1Q157P and 10% JAK2V617F and the other SF3B1K666E and 50% JAK2V617F. A third CR patient had a 50% reduction in U2AF1 469_insAGTATG mutation. Among 13 patients with leukocytosis, 10 (77%) normalized their count or had 50% reduction. Eleven (61%) patients had complete or partial resolution of leukoerythroblastosis.

    iii) Laboratory correlative studies

    Three (50%) of 6 spliceosome-mutated vs. 1 (8%) of 12 unmutated (p=0.045) achieved CR. Spliceosome-mutated patients were also more likely to experience grade-3/4 myelosuppression (67% vs. 25% ; p=0.09). Treatment was associated with suppression of telomerase activity, shortening of telomere length and alteration of hTERT isoform pattern.

    Conclusions: The current study signifies the potential value of telomerase-based treatment strategies in MF and identifies imetelstat as an active drug in that regard. The observed morphologic and molecular remissions confirm selective anti-clonal activity, which has thus far eluded other drugs in MF, including JAK inhibitors. The association between response and spliceosome mutations suggests a broader application for the drug in myeloid malignancies.

    There was buzz surrounding imetelstat going into Thursday's abstract release because the drug may have legitimate disease-modifying potential in bone marrow cancers like myelofibrosis. "

    Incyte's (INCY_) Jakafi is approved to treat myelofibrosis

47.57-1.80(-3.65%)Jul 31 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Tesla Motors, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT
eHealth, Inc.
NasdaqGSThu, Jul 31, 2014 3:59 PM EDT